Contrast media as carriers for local drug delivery -: Successful inhibition of neointimal proliferation in the porcine coronary stent model

被引:99
作者
Scheller, B
Speck, U
Romeike, B
Schmitt, A
Sovak, M
Böhm, M
Stoll, HP
机构
[1] Charite, Inst Radiol, Berlin, Germany
[2] Univ Saarlandes Kliniken, Inst Neuropathol, Holmbergh, Germany
[3] Univ Calif San Diego, Sch Med, Dept Radiol, San Diego, CA 92103 USA
[4] Univ Saarlandes Kliniken, Homburg, Germany
关键词
restenosis; stents; angioplasty; contrast media; taxanes; protaxel; lopromide;
D O I
10.1016/S0195-668X(03)00317-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Lipophilic taxanes can be dissolved in contrast media at significantly higher concentration than in saline. As contrast media have occasionally been observed to delineate the contour of coronary arteries for some seconds they may serve as a matrix for an anti proliferative drug aimed at preventing restenosis. The aim of this study was to test a novel taxane-contrast agent formulation for this new approach in the setting of coronary stenting. Methods and results In cell culture experiments (bovine vascular smooth muscle cells), 60-min incubation with contrast agent-taxane formulations (iopromide-paclitaxel, iopromide-protaxel) induced a significant, concentration-dependent inhibition of vascular smooth muscle cell (VSMC) proliferation over 12 days. Shorter incubation times of 10 and 3 min showed the same efficacy. For in vivo investigation, 16 stents were implanted into the coronary arteries of eight pigs using a 1.3 to 1 overstretch ratio. A control group received iopromide 370 alone while the treatment group was injected with a iopromide-protaxel formulation at a dose of 74 mumol/l, which is far below protaxel. levels inducing systemic toxicity. Quantitative angiography and histomorphometry of the stented arteries asserted statistic equality of the baseline parameters between the control and treatment groups. After 28 days, the treatment group showed a marked reduction of the parameters characterizing in-stent restenosis, especially a 34% reduction of the neointimal area. Conclusions First evidence is provided that using a contrast agent as solvent for a taxane constitutes a new drug delivery mechanism able to inhibit in-stent restenosis in the porcine restenosis model. (C) 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
引用
收藏
页码:1462 / 1467
页数:6
相关论文
共 19 条
[11]   LOCAL-DRUG DELIVERY FOR THE PREVENTION OF RESTENOSIS - FACT, FANCY, AND FUTURE [J].
LINCOFF, AM ;
TOPOL, EJ ;
ELLIS, SG .
CIRCULATION, 1994, 90 (04) :2070-2084
[12]   Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel [J].
Lovich, MA ;
Creel, C ;
Hong, K ;
Hwang, CW ;
Edelman, ER .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (09) :1324-1335
[13]   A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. [J].
Morice, M ;
Serruys, PW ;
Sousa, JE ;
Fajadet, J ;
Hayashi, EB ;
Perin, M ;
Colombo, A ;
Schuler, G ;
Barragan, P ;
Guagliumi, G ;
Molnar, F ;
Falotico, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23) :1773-1780
[14]   Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility [J].
Niethammer, A ;
Gaedicke, G ;
Lode, HN ;
Wrasidlo, W .
BIOCONJUGATE CHEMISTRY, 2001, 12 (03) :414-420
[15]   Demonstration of platinum microcoils in embolized blood vessels in-situ using a modified methyl methacrylate embedding method, and a special cutting and grinding technique [J].
Romeike, BFM ;
Feiden, W .
BIOTECHNIC & HISTOCHEMISTRY, 1998, 73 (04) :198-201
[16]   DRUG-THERAPY - PACLITAXEL (TAXOL) [J].
ROWINSKY, EK ;
DONEHOWER, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (15) :1004-1014
[17]   A new prodrug of paclitaxel: synthesis of Protaxel [J].
Seligson, AL ;
Terry, RC ;
Bressi, JC ;
Douglass, JG ;
Sovak, M .
ANTI-CANCER DRUGS, 2001, 12 (04) :305-313
[18]  
SEONG HJ, 2001, INVEST NEW DRUGS, V19, P113
[19]   Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries [J].
vanderGiessen, WJ ;
Lincoff, AM ;
Schwartz, RS ;
vanBeusekom, HMM ;
Serruys, PW ;
Holmes, DR ;
Ellis, SG ;
Topol, EJ .
CIRCULATION, 1996, 94 (07) :1690-1697